This study investigated mutations in the untranslated regions (UTRs) of EGFR, AKT1, and HRAS genes in Pakistani colorectal cancer patients. Whole-exome sequencing and extensive in silico analysis identified several UTR mutations. These alterations demonstrated significant functional impacts, including the loss or gain of transcription factor binding sites, changes in mRNA stability, and the loss of oncomiR binding sites. The findings suggest that these UTR mutations could dysregulate the expression of these oncogenes and contribute to colorectal cancer progression.
This study focuses on developing novel inhibitors targeting the RAS/RAF pathway, a significant challenge in oncology given the frequency of RAS mutations and acquired resistance to existing treatments. Researchers identified small molecules that covalently bind to a distinct site within the RAS-binding domain of RAF, leading to allosteric disruption of its conformation. This mechanism prevents RAS/RAF interaction and downstream signaling. These compounds demonstrated preclinical antitumor efficacy against various cancers with KRAS, NRAS, and HRAS mutations, as well as wild-type RAS-driven cancers. They also suppressed tumor growth in BRAFV600E melanoma with acquired BRAF inhibitor resistance by preventing RAS signal reactivation.